What we learned from STEP that we didn't already know from SPRINT

BACKGROUND: In view of the aging population, the target value for treatment in elderly hypertensive patients is today a clinically relevant problem. METHODS: STEP and SPRINT studies enrolled elderly subjects with exclusion of previous stroke patients. However, STEP enrolled subjects at lower cardiov...

Descripción completa

Detalles Bibliográficos
Autor principal: Modesti, Pietro Amedeo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Invited Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710416/
https://www.ncbi.nlm.nih.gov/pubmed/34988556
http://dx.doi.org/10.1016/j.ijcrp.2021.200116
Descripción
Sumario:BACKGROUND: In view of the aging population, the target value for treatment in elderly hypertensive patients is today a clinically relevant problem. METHODS: STEP and SPRINT studies enrolled elderly subjects with exclusion of previous stroke patients. However, STEP enrolled subjects at lower cardiovascular risk than SPRINT. RESULTS: In Chinese hypertensive patients aged 60–80 years enrolled in the STEP study, intensive blood pressure treatment (systolic blood pressure target of 110–130 mmHg) reduced the primary composite cardiovascular endpoint and stroke with no effect on cardiovascular death and renal harm, two endpoints significantly affected in SPRINT. CONCLUSION: Differences with SPRINT are the lower cardiovascular risk and CKD prevalence of STEP population.

Ejemplares similares